Citations

Clear

6274 citation(s) found for "To, Andrew".

Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk
Tian, Yu , Kim, Andre E. , Harrison, Tabitha A. , Carreras‐Torres, Robert , Díez‐Obrero, Virginia , Drew, David A. , Huyghe, Jeroen R. , Jordahl, Kristina M. , Obón‐Santacana, Mireia , Ose, Jennifer , Duijnhoven, Fränzel J.B. van , Baurley, James W. , Berndt, Sonja I. , Bishop, D. Timothy , Brenner, Hermann , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Harlid, Sophia , Hoffmeister, Michael , Joshi, Amit D. , Li, Li , Nan, Hongmei , Nassir, Rami , Prentice, Ross L. , Rennert, Gad , Slattery, Martha L. , Thibodeau, Stephen N. , Guelpen, Bethany Van , Visvanathan, Kala , White, Emily , Woods, Michael O. , Wu, Anna H. , Casey, Graham , Kundaje, Anshul , Pardamean, Bens , Thomas, Duncan C. , Tsilidis, Konstantinos K. , Peters, Ulrike , Gauderman, W. James, Chang‐Claude, Jenny , Carreras-Torres, Robert , Drew, David A , Huyghe, Jeroen R , Jordahl, Kristina M , Murphy, Neil , Ulrich, Cornelia M , Ose, Jennifer , Peoples, Anita R , Ruiz-Narvaez, Edward , van Duijnhoven, Fränzel J B , Arndt, Volker , Bishop, D Timothy , Brenner, Hermann , Buchanan, Daniel D , Figueiredo, Jane C , Gruber, Stephen B , Harlid, Sophia , Hoffmeister, Michael , Jenkins, Mark A , Larsson, Susanna C , Marchand, Loïc Le , Li, Li , Giles, Graham G , Milne, Roger L , Nassir, Rami , Ogino, Shuji , Budiarto, Arif , Platz, Elizabeth A. , Potter, John D , Sakoda, Lori C , Schoen, Robert E , Slattery, Martha L , Van Guelpen, Bethany , Visvanathan, Kala , Wolk, Alicja , Wu, Anna H. , Kundaje, Anshul , Moreno, Victor , Pardamean, Bens , Thomas, Duncan C , Tsilidis, Konstantinos K , Chang-Claude, Jenny , Rennert, Gad , Harrison, Tabitha A , Tian, Yu , Nan, Hongmei , Obón-Santacana, Mireia , Diez-Obrero, Virginia , Bien, Stephanie A. , Lin, Yi , Qu, Conghui , Dimou, Niki , Hidaka, Akihisa , Morrison, John L. , Murphy, Neil , Ulrich, Cornelia M. , Shcherbina, Anna , Stern, Mariana Carla , Su, Yu-Ru , Arndt, Volker , Buchanan, Daniel D. , Chan, Andrew T. , Jenkins, Mark A. , Keku, Temitope O , Larsson, Susanna C. , Marchand, Loı̈c Le , Giles, Graham G. , Milne, Roger L. , Potter, John D. , Sakoda, Lori C. , Schoen, Robert E. , Wolk, Alicja , Campbell, Peter T. , Conti, David V. , Gunter, Marc J. , Lewinger, Juan Pablo , Moreno, Vı́ctor , Newcomb, Polly A. , Hsu, Li

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 30, 2022 | Volume: 114 | Issue: 8 | Pages: 1135-1148

10.1093/jnci/djac094 | PMID 35512400 Get It

Abstract Background The use of menopausal hormone therapy (MHT) may interact with genetic variants to influence colorectal cancer (CRC) risk. Methods We conducted a genome-wide, gene-environment interaction between single nucleotide polymorphisms and the use of any MHT, estrogen only, and combined estrogen-progestogen therapy with CRC risk, among 28 486 postmenopausal women (11 519 CRC patients and 16 967 participants without CRC) from 38 studies, using logistic regression, 2-step method, and 2– or 3–degree-of-freedom joint test. A set-based score test was applied for rare genetic variants. Results The use of any MHT, estrogen only and estrogen-progestogen were associated with a reduced CRC risk (odds ratio [OR] = 0.71, 95% confidence interval [CI] = 0.64 to 0.78; OR = 0.65, 95% CI = 0.53 to 0.79; and OR = 0.73, 95% CI = 0.59 to 0.90, respectively). The 2-step method identified a statistically significant interaction between a GRIN2B variant rs117868593 and MHT use, whereby MHT-associated CRC risk was statistically significantly reduced in women with the GG genotype (OR = 0.68, 95% CI = 0.64 to 0.72) but not within strata of GC or CC genotypes. A statistically significant interaction between a DCBLD1 intronic variant at 6q22.1 (rs10782186) and MHT use was identified by the 2–degree-of-freedom joint test. The MHT-associated CRC risk was reduced with increasing number of rs10782186-C alleles, showing odds ratios of 0.78 (95% CI = 0.70 to 0.87) for TT, 0.68 (95% CI = 0.63 to 0.73) for TC, and 0.66 (95% CI = 0.60 to 0.74) for CC genotypes. In addition, 5 genes in rare variant analysis showed suggestive interactions with MHT (2-sided P < 1.2 × 10−4). Conclusion Genetic variants that modify the association between MHT and CRC risk were identified, offering new insights into pathways of CRC carcinogenesis and potential mechanisms involved.
Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection
Niesen, Michiel J.M. , Matson, Robert P. , Puranik, Arjun, O’Horo, John C. , Pawlowski, Colin , Vachon, Celine M, Virk, Abinash , Swift, Melanie D. , Speicher, Leigh L. , Gordon, Joel , Geyer, Holly L. , Vachon, Celine, Challener, Douglas , Swift, Melanie, Speicher, Leigh, Geyer, Holly, Lenehan, Patrick J , Soundararajan, Venky , Badley, Andrew, O'Horo, John C , Swift, Melanie D , Challener, Douglas W. , Lenehan, Patrick J. , Venkatakrishnan, A J , Soundararajan, Venky , Badley, Andrew D.

Mayo Clinic

PNAS Nexus | April 28, 2022 | Volume: 1 | Issue: 2 | Pages: No page available

10.1093/pnasnexus/pgac042 | PMID 36713312 Get It

Abstract As of 2021 November 29, booster vaccination against SARS-CoV-2 infection has been recommended for all individuals aged 18 years and older in the United States. A key reason for this recommendation is the expectation that a booster vaccine dose can alleviate observed waning of vaccine effectiveness (VE). Although initial reports of booster effectiveness have been positive, the level of protection from booster vaccination is unclear. We conducted two studies to assess the impact of booster vaccination, with BNT162b2 or mRNA-1273, on the incidence of SARS-CoV-2 infection between August and December 2021. We first compared SARS-CoV-2 infection incidence in cohorts of 3-dose vaccine recipients to incidence in matched cohorts of 2-dose vaccine recipients (cohort size = 24,539 for BNT162b2 and 14,004 for mRNA-1273). Additionally, we applied a test-negative study design to compare the level of protection against symptomatic infection in 3-dose recipients to that observed in recent 2-dose primary vaccine series recipients. The 3-dose recipients experienced a significantly lower incidence rate of SARS-CoV-2 infection than the matched 2-dose cohorts (BNT162b2 Incidence Rate Ratio: 0.11, 95% CI: 0.09 to 0.13 and mRNA-1273 IRR: 0.11, 95% CI: 0.08 to 0.15). Results from the test-negative study showed the third vaccine dose mitigated waning of VE, with the risk of symptomatic infection in 3-dose recipients being comparable to that observed 7 to 73 days after the primary vaccine series. These results show that 3-dose vaccine regimens with BNT162b2 or mRNA-1273 are effective at reducing SARS-CoV-2 infection and support the widespread administration of booster vaccine doses.
Predictive metabolic networks reveal sex‐ and APOE genotype‐specific metabolic signatures and drivers for precision medicine in Alzheimer's disease
Chang, Rui , Trushina, Eugenia , Zhu, Kuixi , Zaidi, Syed Shujaat Ali , Lau, Branden M, Moein, Sara, He, Qianying, Alamprese, Melissa , Vagnerova, Barbora, Tang, Andrew, Vijayan, Ramachandran , Liu, Yan‐Yun , Saykin, Andrew J. , Young‐Pearse, Tracy L. , Saykin, Andrew J , Trushina, Eugenia , Kueider‐Paisley, Alexandra , Tang, Andrew, Vijayan, Ramachandran, Brinton, Roberta Dı́az , Kaddurah‐Daouk, Rima

Mayo Clinic

Alzheimer's & Dementia | April 28, 2022 | Volume: 19 | Issue: 2 | Pages: 518-531

10.1002/alz.12675 | PMID 35481667 Get It

Abstract Introduction Late‐onset Alzheimer's disease (LOAD) is a complex neurodegenerative disease characterized by multiple progressive stages, glucose metabolic dysregulation, Alzheimer's disease (AD) pathology, and inexorable cognitive decline. Discovery of metabolic profiles unique to sex, apolipoprotein E ( APOE ) genotype, and stage of disease progression could provide critical insights for personalized LOAD medicine. Methods Sex‐ and APOE ‐specific metabolic networks were constructed based on changes in 127 metabolites of 656 serum samples from the Alzheimer's Disease Neuroimaging Initiative cohort. Results Application of an advanced analytical platform identified metabolic drivers and signatures clustered with sex and/or APOE ɛ4, establishing patient‐specific biomarkers predictive of disease state that significantly associated with cognitive function. Presence of the APOE ɛ4 shifts metabolic signatures to a phosphatidylcholine‐focused profile overriding sex‐specific differences in serum metabolites of AD patients. Discussion These findings provide an initial but critical step in developing a diagnostic platform for personalized medicine by integrating metabolomic profiling and cognitive assessments to identify targeted precision therapeutics for AD patient subgroups through computational network modeling.
A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse
Greenberg, Benjamin , Bowen, James D. , Caggiano, Anthony O. , Warrington, Arthur E. , Zhao, Ping , Greenberg, Benjamin M , Álvarez, Enrique , Rodriguez, Moses , Eisen, Andrew

Mayo Clinic

Multiple Sclerosis Journal - Experimental, Translational and Clinical | April 26, 2022 | Volume: 8 | Issue: 2 | Pages: No page available

10.1177/20552173221091475 | PMID 35496758 Get It

Background Recombinant human immunoglobulin M22 (rHIgM22) has promoted remyelination in animal models and was well tolerated in people with clinically stable multiple sclerosis. Objective Safety/tolerability of a single rHIgM22 dose was investigated following an acute relapse and to determine whether this enhanced CNS/CSF concentrations. Methods Adults (N = 27) with acute relapse were assigned to rHIgM22 (0.5 or 2.0 mg/kg) or placebo. Study included screening/steroid administration periods and 10 study visits over 6 months. rHIgM22 CSF concentrations were assessed on days 2 and 29. Pharmacokinetic and safety samples were taken for up to 60 days. Assessments included adverse events and other clinical measures. Brain magnetic resonance imaging was performed with/without gadolinium. Results rHIgM22 CSF levels were consistent with dose-dependent concentration on both days 2 and 29. Infusion was generally well tolerated during an acute relapse. Immunogenicity was mild. Most adverse events did not appear to be dose dependent, were mild/moderate, and were events often associated with multiple sclerosis. Conclusion Although limited by high variability and small sample size, the data suggest enhanced CNS uptake associated with a drop in CSF levels. This study demonstrated safety of an antibody directed to myelin and oligodendrocytes in the course of active demyelinating disease. Further research into rHIgM22 is warranted. ClinicalTrials.gov: NCT02398461 https://clinicaltrials.gov/ct2/show/NCT02398461
71 Adult Patient's Opinions on Surgical Correction of Congenital Penile Curvature
Ziegelmann, M, Winkelman, Andrew J, Holler, Jordan T. , Breyer, B, Herndon, A, Villanueva, C, Kern, N, Ziegelmann, M, Villanueva, Carlos

Mayo Clinic

The Journal of Sexual Medicine | April 26, 2022 | Volume: 19 | Issue: Supplement_1 | Pages: S37-S38

10.1016/j.jsxm.2022.01.083 Get It

ABSTRACT Introduction Congenital penile curvature is common and presents with varying levels of severity. The curvature may present during infancy or post-pubertal. Historically, treatment has consisted of surgical correction, typically with penile plication or complex grafting procedures. Most pediatric urologists recommend surgical management for penile curvature (PC) based on curvature severity, with previous work identifying ≥ 30° as a common threshold to recommend correction. Objective To assess adult patients’ opinions on willingness to consider surgical correction for PC in order to determine if this aligns with pediatric urologists’ opinions. Methods In this cross-sectional study, a survey was administered to adult patients and their partners (> 18 years of age) in general adult urology clinics at 3 geographically separate institutions. The survey consisted of unlabeled images of penis models with varying degrees of PC (range 10-90°). Respondents were asked to select the images they would want surgically corrected for themselves or their partners. Univariable and multivariable analyses were performed to identify demographic variables associated with willingness to consider correction (p-values < .05 considered significant). Results Response rate was 77% (300/388). The majority (80%) of participants chose to surgically correct PC, however 20% chose to not surgically correct any degree of PC. Most participants were male (70%), married (62%), heterosexual (92%), and did not work in healthcare (80%) (Table 1). Among those who endorsed willingness to surgically correct PC, the average threshold for correction was 40.5° (SD 25.3). On univariable analysis, there was a significant difference in willingness to undergo PC correction based on gender, age groups, sexual orientation, and region (Table 1). Male patients were more likely to consider surgery at a lower degree of PC compared to females (36.6° vs 50.6°, p<.001). Those who identified as heterosexual also had a lower threshold for correction compared to those identifying as LGBTQ (39.6° vs 56.4°, p=.015). Midwestern residents endorsed an average threshold for correction of 21.5° compared to other regions varying between 40° to 60° (p<.001). Regionality differences remained true on multivariable analysis when accounting for all demographic features (p<.001). Conclusions In surveying adult patients, we identified an average PC threshold of 40° beyond which surgical correction was desired. Females and LGBTQ+ participants had a higher threshold for surgical correction, but when accounting for all demographic factors, only residence in the Midwest US was associated with a lower threshold for correction. Disclosure No
The impact of planned parental follow‐up on compliance with opioids disposal following pediatric surgery
Adler, Adam C. , Bryant, Brittany E. , Baszynski, David, Lee, Andrew , Medellin, Eduardo , McCarthy, Jennifer , White, Andrea T. , Nathanson, Brian H. , Chandrakantan, Arvind , White, Andrea

Mayo Clinic

Pediatric Anesthesia | April 21, 2022 | Volume: 32 | Issue: 8 | Pages: 970-972

10.1111/pan.14467 | PMID 35445783 Get It

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
Li, Maggie , Beck, Evan J. , Laeyendecker, Oliver , Eby, Yolanda , Wouters, Camille, Chiklis, Gregory R., Block, William , McKie, Robert O., Joyner, Michael J. , Wiltshire, Timothy D. , Dietz, Allan B. , Gniadek, Thomas J. , Shapiro, Arell, Yarava, Anusha , Lane, Karen , Bloch, Evan M. , Cachay, Edward R. , Huamán, Moisés A. , Fukuta, Yuriko , Patel, Bela , Heath, Sonya L. , Gerber, Jonathan M. , Sullivan, David , Wiltshire, Timothy D , Dietz, Allan B , Hanley, Daniel F , Bloch, Evan M , Shoham, Shmuel , Cachay, Edward R , Huaman, Moises A , Levine, Adam C , Paxton, James H , Gerber, Jonathan M , Gebo, Kelly A , Casadevall, Arturo , Sullivan, David J , Joyner, Michael J , Laeyendecker, Oliver , Tobian, Aaron A.R. , Caturegli, Patrizio , Block, William, Hanley, Daniel F. , Shoham, Shmuel , Meisenberg, Barry R. , Anjan, Shweta , Casadevall, Arturo , Pekosz, Andrew

Mayo Clinic

Blood Advances | April 20, 2022 | Volume: 6 | Issue: 12 | Pages: 3678-3683

10.1182/bloodadvances.2022007410 | PMID 35443020 Get It

Abstract The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The Food and Drug Administration currently allows outpatient CCP for the immunosuppressed. Viral-specific antibody levels in CCP can range 10- to 100-fold between donors, unlike the uniform viral-specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-δ/pre-ο donor units obtained before March 2021, 20 post-δ COVID-19/postvaccination units, and 1 pre-δ/pre-ο hyperimmunoglobulin preparation for variant-specific virus (vaccine-related isolate [WA-1], δ, and ο) neutralization correlated to Euroimmun S1 immunoglobulin G antibody levels. We observed a two- to fourfold and 20- to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to δ or ο, respectively. CCP antibody levels in the upper 10% of the 108 donations as well as 100% of the post-δ COVID-19/postvaccination units and the hyperimmunoglobulin effectively neutralized all 3 variants. High-titer CCP neutralizes SARS-CoV-2 variants despite no previous donor exposure to the variants.
A Metabolomic Severity Score for Airflow Obstruction and Emphysema
Godbole, Suneeta , Pratte, Katherine , Hill, Andrew , Hastie, Annette T. , Peters, Stephen P. , Gregory, Andrew , Ortega, Victor E. , DeMeo, Dawn L. , Bhatt, Surya P. , Wells, J. Michael , Barjaktarević, Igor , Stringer, Kathleen A. , Comellas, Alejandro P. , O’Neal, Wanda K. , Kechris, Katerina , Hill, Andrew , Gregory, Andrew , Barjaktarevic, Igor , Stringer, Kathleen A , Kechris, Katerina , O'Neal, Wanda K , Comellas, Alejandro P , Bhatt, Surya P , Wells, J Michael , Labaki, Wassim W. , Moll, Matthew , Cho, Michael H. , Bowler, Russell P.

Mayo Clinic

Metabolites | April 19, 2022 | Volume: 12 | Issue: 5 | Pages: 368

10.3390/metabo12050368 | PMID 35629872 Get It

Chronic obstructive pulmonary disease (COPD) is a disease with marked metabolic disturbance. Previous studies have shown the association between single metabolites and lung function for COPD, but whether a combination of metabolites could predict phenotype is unknown. We developed metabolomic severity scores using plasma metabolomics from the Metabolon platform from two US cohorts of ever-smokers: the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) (n = 648; training/testing cohort; 72% non-Hispanic, white; average age 63 years) and the COPDGene Study (n = 1120; validation cohort; 92% non-Hispanic, white; average age 67 years). Separate adaptive LASSO (adaLASSO) models were used to model forced expiratory volume at one second (FEV1) and MESA-adjusted lung density using 762 metabolites common between studies. Metabolite coefficients selected by the adaLASSO procedure were used to create a metabolomic severity score (metSS) for each outcome. A total of 132 metabolites were selected to create a metSS for FEV1. The metSS-only models explained 64.8% and 31.7% of the variability in FEV1 in the training and validation cohorts, respectively. For MESA-adjusted lung density, 129 metabolites were selected, and metSS-only models explained 59.0% of the variability in the training cohort and 17.4% in the validation cohort. Regression models including both clinical covariates and the metSS explained more variability than either the clinical covariate or metSS-only models (53.4% vs. 46.4% and 31.6%) in the validation dataset. The metabolomic pathways for arginine biosynthesis; aminoacyl-tRNA biosynthesis; and glycine, serine, and threonine pathway were enriched by adaLASSO metabolites for FEV1. This is the first demonstration of a respiratory metabolomic severity score, which shows how a metSS can add explanation of variance to clinical predictors of FEV1 and MESA-adjusted lung density. The advantage of a comprehensive metSS is that it explains more disease than individual metabolites and can account for substantial collinearity among classes of metabolites. Future studies should be performed to determine whether metSSs are similar in younger, and more racially and ethnically diverse populations as well as whether a metabolomic severity score can predict disease development in individuals who do not yet have COPD.
Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region
Jordahl, Kristina M. , Shcherbina, Anna , Kim, Andre E. , Arndt, Volker , Baurley, James W. , Berndt, Sonja I. , Bishop, D. Timothy , Bouras, Emmanouil , Brenner, Hermann , Carreras‐Torres, Robert , Casey, Graham , Conti, David V. , Díez‐Obrero, Virginia , Dimou, Niki , Drew, David A. , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gsur, Andrea , Harlid, Sophia , Harrison, Tabitha A. , Hoffmeister, Michael , Huyghe, Jeroen R. , Joshi, Amit D. , Li, Li , Nan, Hongmei , Nassir, Rami , Obón‐Santacana, Mireia , Ose, Jennifer , Pai, Rish K. , Papadimitriou, Nikos , Pardamean, Bens , Prentice, Ross L. , Rennert, Gad , Scacheri, Peter C. , Schmit, Stephanie L. , Slattery, Martha L. , Thibodeau, Stephen N. , Thomas, Duncan C. , Tian, Yu , Tsilidis, Konstantinos K. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Visvanathan, Kala , Vodička, Pavel , White, Emily , Woods, Michael O. , Wu, Anna H. , Zemlianskaia, Natalia , Chang‐Claude, Jenny , Gauderman, W. James , Kundaje, Anshul , Peters, Ulrike , Arndt, Volker , Bien, Stephanie A , Bishop, D Timothy , Brenner, Hermann , Buchanan, Daniel D , Campbell, Peter T , Carreras-Torres, Robert , Chan, Andrew T , Dampier, Christopher H , Dimou, Niki , Drew, David A , Figueiredo, Jane C , Giles, Graham G , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Hampel, Heather , Harlid, Sophia , Harrison, Tabitha A , Hidaka, Akihisa , Hoffmeister, Michael , Huyghe, Jeroen R , Larsson, Susanna C , Mahesworo, Bharuno , Moreno, Victor , Morrison, John L , Nassir, Rami , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Peoples, Anita R , Pharoah, Paul D P , Platz, Elizabeth A. , Potter, John D , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Schmit, Stephanie L , Schoen, Robert E , Slattery, Martha L , Stern, Mariana Carla , Thomas, Duncan C , Tian, Yu , Tsilidis, Konstantinos K , Ulrich, Cornelia M , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Visvanathan, Kala , Wolk, Alicja , Woods, Michael O , Chang-Claude, Jenny , Gauderman, W James , Hsu, Li , Kundaje, Anshul , Peters, Ulrike , Pardamean, Bens , Bouras, Emmanouil , Conti, David V , Nan, Hongmei , Obón-Santacana, Mireia , Papadimitriou, Nikos , Shcherbina, Anna , Vodicka, Pavel , Diez-Obrero, Virginia , Su, Yu-Ru , Lin, Yi , Wang, Jun , Qu, Conghui , Albanes, Demetrius , Bien, Stephanie A. , Buchanan, Daniel D. , Budiarto, Arif , Campbell, Peter T. , Cenggoro, Tjeng Wawan , Chan, Andrew T. , Dampier, Christopher H. , Devall, Matthew A M , Giles, Graham G. , Gunter, Marc J. , Hampel, Heather , Hidaka, Akihisa , Jenkins, Mark A. , Keku, Temitope O , Larsson, Susanna C. , Marchand, Loı̈c Le , Lewinger, Juan Pablo , Moreno, Vı́ctor , Morrison, John L. , Murphy, Neil , Newcomb, Polly A. , Palmer, Julie R. , Pharoah, Paul D.P. , Potter, John D. , Sakoda, Lori C. , Schoen, Robert E. , Tangen, Catherine M. , Ulrich, Cornelia M. , Wolk, Alicja

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 19, 2022 | Volume: 31 | Issue: 5 | Pages: 1077-1089

10.1158/1055-9965.epi-21-1003 | PMID 35438744 Get It

Abstract Background: Currently known associations between common genetic variants and colorectal cancer explain less than half of its heritability of 25%. As alcohol consumption has a J-shape association with colorectal cancer risk, nondrinking and heavy drinking are both risk factors for colorectal cancer. Methods: Individual-level data was pooled from the Colon Cancer Family Registry, Colorectal Transdisciplinary Study, and Genetics and Epidemiology of Colorectal Cancer Consortium to compare nondrinkers (≤1 g/day) and heavy drinkers (>28 g/day) with light-to-moderate drinkers (1–28 g/day) in GxE analyses. To improve power, we implemented joint 2df and 3df tests and a novel two-step method that modifies the weighted hypothesis testing framework. We prioritized putative causal variants by predicting allelic effects using support vector machine models. Results: For nondrinking as compared with light-to-moderate drinking, the hybrid two-step approach identified 13 significant SNPs with pairwise r2 > 0.9 in the 10q24.2/COX15 region. When stratified by alcohol intake, the A allele of lead SNP rs2300985 has a dose–response increase in risk of colorectal cancer as compared with the G allele in light-to-moderate drinkers [OR for GA genotype = 1.11; 95% confidence interval (CI), 1.06–1.17; OR for AA genotype = 1.22; 95% CI, 1.14–1.31], but not in nondrinkers or heavy drinkers. Among the correlated candidate SNPs in the 10q24.2/COX15 region, rs1318920 was predicted to disrupt an HNF4 transcription factor binding motif. Conclusions: Our study suggests that the association with colorectal cancer in 10q24.2/COX15 observed in genome-wide association study is strongest in nondrinkers. We also identified rs1318920 as the putative causal regulatory variant for the region. Impact: The study identifies multifaceted evidence of a possible functional effect for rs1318920.
Letters of reference for PGY1 pharmacy residency candidates: A survey of residency program directors and opinion statement
Dy‐Boarman, Eliza A. , McCreary, Erin K. , Nisly, Sarah A. , Paloucek, Frank P. , Peterson, David M., Smith, Andrew , Schramm, Garrett E. , Skrupky, Lee P. , Gurgle, Holly E. , Isaacs, Alex N. , McCreary, Erin K , Peterson, David M.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | April 19, 2022 | Volume: 4 | Issue: 3 | Pages: 379-389

10.1002/jac5.1370 Get It

AbstractIntroductionAlthough letters of reference (LORs) are required for postgraduate year one (PGY1) residency applications and used to distinguish between candidates, an evaluation of residency program director (RPD) perceptions and values surrounding LORs has not been described.ObjectiveThe aim of the study was to describe PGY1 RPDs' processes, values, and perceptions surrounding LORs.MethodsThis was a cross‐sectional descriptive survey. After assessing content validity, the Education and Training Practice and Research Network (PRN) taskforce sent a 25‐item electronic survey to 1266 PGY1 RPDs. Survey questions captured program demographics, LOR requirements, processes for LOR review, and perceptions about the value of LORs. Two open‐ended questions solicited suggestions for LORs and the existing standardized form; responses were evaluated via thematic analysis.ResultsA total of 291 (24%) programs completed the survey. LORs were rated as extremely or quite valuable by 82% of respondents and moderately valuable by 16% of respondents. Scoring rubrics for LOR evaluation were used by 79% of programs, and performance ratings were reported to impact interview consideration by a majority of programs. Accuracy, detailed comments, and inclusion of specific candidate strengths and areas for improvement were rated as extremely or quite important characteristics by 90% or more of respondents. Specific strengths were reported to be present in LORs more than half of the time by 81% of programs; however, accuracy, detailed comments, and inclusion of specific areas for improvement were only reported to be present about half the time or less by 41%, 63%, and 63% of respondents. Among 207 suggestions submitted to improve LOR utility, common themes included a desire for LOR authors to have candid discussions with candidates prior to letter writing, to contextualize their relationship with the candidate, and provide honest and specific assessments.ConclusionLORs remain highly valued by PGY1 RPDs during application review. Several notable findings were observed, resulting in recommendations for LOR authors, residency applicants, and the standardized LOR form.